TITLE:
SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)

CONDITION:
Alzheimer's Disease

INTERVENTION:
SGS742

SUMMARY:

      The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and
      cognition in patients with mild to moderate Alzheimer's disease.
    

DETAILED DESCRIPTION:

      SGS742 is a GABA(B) receptor antagonist. It is an orally active drug and possesses
      neurochemical and psychopharmacologic features that suggest it could improve memory and
      cognition in humans. The primary objective of the SGS742 clinical trial will be to determine
      the effect of SGS742 on memory and cognition in individuals diagnosed with mild to moderate
      Alzheimer's disease. The duration of the study is 3 months with 5 clinic visits.
    

ELIGIBILITY:
Gender: All
Age: 55 Years to 90 Years
Criteria:

        Inclusion Criteria:

          -  55 to 90 years of age

          -  Diagnosed with mild to moderate Alzheimer's disease

          -  Willing caregiver

          -  In general good health

        Exclusion Criteria:

          -  Call 1-877-MY-MEMORY and ask to be referred to a study center located near you for
             entry criteria information.

        Prohibited Meds:

          -  Alzheimer's medications (Aricept, Exelon, Remydl, Nemenda)
      
